BOSTON--(BUSINESS WIRE)--
Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company developing innovative and proprietary treatments for nocturnal leg cramps (NLC), spasms associated with severe neuromuscular conditions such as MS and ALS, and exercise-associated muscle cramps, today reported financial results for the quarter ended March 31, 2016 and provided an update on its clinical development and corporate activities.
Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company developing innovative and proprietary treatments for nocturnal leg cramps (NLC), spasms associated with severe neuromuscular conditions such as MS and ALS, and exercise-associated muscle cramps, today reported financial results for the quarter ended March 31, 2016 and provided an update on its clinical development and corporate activities.
